Immune Response after mRNA COVID-19 Vaccination in Lung Transplant Recipients: A 6-Month Follow-Up.
COVID-19
T cell response
humoral response
immunosuppressive drugs
lung transplant recipients
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
15 Jul 2022
15 Jul 2022
Historique:
received:
08
06
2022
revised:
11
07
2022
accepted:
12
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
This prospective cohort study analyzed the immune response to COVID-19 mRNA vaccines in lung transplant recipients (LuTRs) compared to healthy controls (HCs) at a 6-month follow-up. After the first two doses of either BNT162b2 or mRNA-1273, SARS-CoV-2 antibodies were measured in LuTRs ( Seroconversion rates were 94% and 100% after the first and second vaccine dose, respectively, in HCs, while only 19% and 56% of LuTRs developed antibodies. Furthermore, 22 of 24 LuTRs who received the third vaccine dose showed seroconversion (five of seven primary non-responders and 17 of 17 primary responders). A T cell response against SARS-CoV-2-spike S1 and/or S2 was detected in 100% (16/16) of HCs and 50% (8/16) of LuTRs. The data suggest that LuTRs have reduced humoral and cellular immune responses after two doses of COVID-19 mRNA vaccination when compared to HCs. A third dose may be of substantial benefit.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
This prospective cohort study analyzed the immune response to COVID-19 mRNA vaccines in lung transplant recipients (LuTRs) compared to healthy controls (HCs) at a 6-month follow-up.
METHODS
METHODS
After the first two doses of either BNT162b2 or mRNA-1273, SARS-CoV-2 antibodies were measured in LuTRs (
RESULTS
RESULTS
Seroconversion rates were 94% and 100% after the first and second vaccine dose, respectively, in HCs, while only 19% and 56% of LuTRs developed antibodies. Furthermore, 22 of 24 LuTRs who received the third vaccine dose showed seroconversion (five of seven primary non-responders and 17 of 17 primary responders). A T cell response against SARS-CoV-2-spike S1 and/or S2 was detected in 100% (16/16) of HCs and 50% (8/16) of LuTRs.
CONCLUSIONS
CONCLUSIONS
The data suggest that LuTRs have reduced humoral and cellular immune responses after two doses of COVID-19 mRNA vaccination when compared to HCs. A third dose may be of substantial benefit.
Identifiants
pubmed: 35891294
pii: vaccines10071130
doi: 10.3390/vaccines10071130
pmc: PMC9318026
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Rheum Dis. 2021 Oct;80(10):1312-1316
pubmed: 33958324
Front Immunol. 2022 Jun 01;13:906225
pubmed: 35720376
Transplantation. 2022 Apr 1;106(4):e238-e239
pubmed: 35030156
Biopreserv Biobank. 2018 Dec;16(6):477-482
pubmed: 30335475
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
Transplantation. 2021 Nov 1;105(11):e270-e271
pubmed: 34284420
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
J Heart Lung Transplant. 2021 Dec;40(12):1579-1588
pubmed: 34456108
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33483360
Curr Opin Organ Transplant. 2012 Dec;17(6):601-8
pubmed: 23042206
Vaccines (Basel). 2022 Jun 09;10(6):
pubmed: 35746528
J Heart Lung Transplant. 2021 Aug;40(8):754-758
pubmed: 34120839
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Transplantation. 2022 Mar 1;106(3):e183-e184
pubmed: 34856599
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34117116
Am J Transplant. 2021 Aug;21(8):2727-2739
pubmed: 34036720
Ann Rheum Dis. 2021 Oct;80(10):1345-1350
pubmed: 34285048
Transpl Immunol. 2022 Jun;72:101599
pubmed: 35390480
Transpl Infect Dis. 2020 Dec;22(6):e13364
pubmed: 32521074
Ann Thorac Surg. 2021 May;111(5):e343-e345
pubmed: 33347850
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ann Intern Med. 2022 Feb;175(2):226-233
pubmed: 34807716